Dermagen Reports Successful Phase I/IIa Clinical Trial for Atopic Dermatitis
07-Dec-2009 -
DermaGen AB - part of the Karolinska Development dermatology and wound healing company Pergamum - announced that Dermagen AB has received promising results from a clinical Phase I/IIa study. DermaGen AB is developing a novel antimicrobial peptide (AMP) treatment for atopic dermatitis. Atopic ...
anti-infectives
antibiotics
atopic dermatitis
+8